Methodological approaches to the assessment of cognitive symptoms during psychopharmacotherapy

Close metadata

Recommended articles:

Posttraumatic stress disorder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68

Dynamics of cognitive functions using the rehabilitation program of cognitive training. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):102-112

Controversial issues of diagnosis and theoretical concepts of schizophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24

Psychological concepts — design of clinical models of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31

Pharmacotherapy of schizophrenia: clinical and some age-related aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50

Clinical systematics of chronic delusional psychoses in schizophrenia and schizophrenia-spectrum pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):65-74

Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):75-81

Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12

Metabolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):13-20

Polymorphic variants in the cluster of genes encoding trace amine receptors and cognitive functioning in patients with schizophrenia spectrum disorders and healthy controls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):122-128

Keywords:

cognitive functions

schizophrenia

psychopharmacotherapy

Authors:

Tsygankov B.D.

Moskva

Khannanova A.N.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

List of references:

Addington J., Addington D., Maticka-Tyndale E.Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res 1991; 4:123-134.
Beasley C.M.Jr., Tollefson G., Tran P. et al.Olanzapine versus haloperidol: acute phase results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology 1996; 14:111-123.
Breier A., Buchanan R.W., Irish D., Carpenter W.T.Jr.Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiat 1993; 44:1145-1149.
Buchanan R.W., Holstein C., Brier A.The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiat 1994; 36: 717-725.
Carpenter W.T., Gold J.M.Another view of therapy for cognition in schizophrenia. Biological Psychiat 2002; 51: 969-971.
Casey D.E.Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109-120.
Chouinard G.Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995; 15: Suppl 1: 36S-44S.
Davidson M., Galderisi S., Weiser M. et al.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiat 2009; 166: 6: 675-82.
Davidson M., Keefe R.S.E.Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 1995; 17: 123-129.
Davis S.M., Koch G.G., Davis C.E., LaVange L.M.Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull 2003; 29: 73-80.
Delucchi K., Bostrom A.Small sample longitudinal clinical trials with missing data: a comparison of analytic methods. Psychol Methods 1999; 4: 108-116.
Essock S.M., Hargreaves W.A., Covell N.H., Goethe J.Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32: 683-697.
Farde L., Nordstrom A.-L., Wiesel F.-A. et al.Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiat 1992; 49: 538-544.
Fleischhacker W.W., Keet I.P., Kahn R.S.EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res 2005; 78: 2-3: 147-156.
Gallhofer B., Bauer U., Lis S. et al.Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6: Suppl 2: 13-20.
Goldberg T.E., Goldman R.S., Burdick K.E. et al.Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiat 2007; 64: 10: 1115-1122.
Green M.F.What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiat 1996; 153: 321-330.
Green M.F., Marder S.R., Glynn S.M. et al.The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiat 2002; 51: 972-978.
Harvey P.D., Howanitz E., Parrella M. et al.Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiat 1998; 155: 1080-1086.
Harvey P.D., Keefe R.S.Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiat 2001; 158: 2: 176-184.
Heaton R.K., Paulsen J.S., McAdams L.A. et al.Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch Gen Psychiat 1994; 51: 469-476.
Jones P.B., Barnes T.R., Davies L. et al.Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiat 2006; 63: 10: 1079-1087.
Kane J., Honigfeld G., Singer J., Meltzer H.Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiat 1988; 45: 789-796.
Keefe R.S., Bilder R.M., Davis S.M. et al.CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiat 2007; 64: 6: 633-647.
Keefe R.S., Mohs R.C., Bilder R.M. et al.Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003; 29: 1: 45-55.
Keefe R.S.E., Perkins S., Silva S.M., Lieberman J.A.The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201-222.
Keefe R.S., Seidman L.J., Christensen B.K. et al.HGDH Research Group. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiat 2006; 59: 2: 97-105.
Kern R.S., Green M.F., Marshall B.D.Jr. et al.Verbal learning in schizophrenia: effects of novel antipsychotic medication. Schizophr Bull 1999.
Leucht S., Kissling W., Davis J.M.Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 10: 1591-602.
Lieberman J.A., Safferman A.Z., Pollack S. et al.Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiat 1994; 151: 1744-175.
Lindenmeyer J.-P., Iskander A., Park M. et al.Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics: a prospective study. J Clin Psychiat 1998; 59: 521-527.
Lindström E., Eriksson B., Hellgren A. et al.Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402-412.
Manschreck T.C., Boshes R.A.The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiat 2007; 15: 5: 245-258.
Marder S.R., Meibach R.C.Risperidone in the treatment of schizophrenia. Am J Psychiat 1994; 151: 825-835.
Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F.Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiat 1990; 41:892-897.
Meltzer H.Y., McGurk S.R.The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255.
Mortimer A.M. First-line atypical antipsychotics for schizophrenia are appropriate - with psychosocial interventions Psychiat Bull 2001; 25: 287-288.
Obuchowski N.A.Sample size calculations in studies of test accuracy. Stat Methods Med Res 1998; 7: 371-392.
Purdon S.E., Jones B.D., Stip E. et al.Canadian Collaborative Group for Research in Schizophrenia: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiat 2000; 57: 249-258.
Rosenheck R., Cramer J., Xu W. et al.A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-815.
Rosenheck R., Perlick D., Bingham S. et al.Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003; 290: 20: 2693-2702.
Rossi A., Mancini F., Stratta P. et al.Risperidone, negative symptoms, and cognitive deficits in schizophrenia: an open study. Acta Psychiat Scand 1997; 95: 40-43.
Sartorius N., Fleischhacker W.W., Gjerris A. et al.The usefulness and use of second generation antipsychotic medication. Curr. Opin. Psychiat 2003; 16: Suppl 1: S44.
Sax K.W., Strakowski S.M., Keck P.E.Jr.Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998; 33: 151-155.
Seidman L.J., Pepple J.R., Faraone S.V.Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiat 1993; 33: 575-584.
Serper M.R., Chou J.C.Y.Novel neuroleptics improve attentional functioning in schizophrenic patients. CNS Spectrums 1997; 2: 56-60.
Sevy S., Davidson M.The cost of cognitive impairment in schizophrenia. Schizophr Res 1995; 17: 1-3.
Simpson G.M., Lindenmayer J.P.Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17: 194-220.
Spitzer M.The psychopathology, neuropsychology, and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiat and Clin Neuroscie 1993; 243: 57-70.
Strauss M.J.Relations of symptoms to cognitive deficits in schizophrenia Schizophr Bull 1993; 19: 2: 215-231.
Stroup T.S., McEvoy J.P., Swartz M.S. et al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31.
Tandon R., Belmaker R.H., Gattaz W.F. et al.World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008, 100: 20-38.
Velligan D.I., Miller A.L.Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment J Clin Psychiat 1999; 60: Suppl 23: 25-28.
Zahn T., Pickar D., Haier R.Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994; 13: 133-144.

Close metadata